Project Grant R01CA306526
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $678K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06510, USA
Similar Awards
- Federal Grant Award Summary New York University School of Medicine received a $714,110 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective September 1, 2025, through August 31, 2030. The award supports research titled "Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification," which aims to develop and validate predictive biomarkers for risk stratification in...
- Federal Grant Award Summary Yale University received a $672,371 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2028. The grant funds development of ultra-sensitive mass spectrometry-based immunopeptidomics technology utilizing digital microfluidics to identify tumor-specific antigens (TSAs) for cancer immunotherapy applications. The project addresses current...
- Federal Grant Award Summary Yale University received a $150,104 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded January 16, 2026, with a completion date of August 31, 2028. This award supports research investigating the impact of aberrant 5-methylcytosine (M5C) messenger RNA (mRNA) modifications on translation initiation and cancer development. The research focuses on determining how dose-sensitive M5C modifications in...
- Federal Grant Award Summary Yale University received a $607,690 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on May 6, 2026, with a completion date of April 30, 2031. The grant funds development of an magnetic resonance (MR)-based imaging platform for high-resolution simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM), an aggressive and chemotherapy-resistant...
- Federal Grant Award Summary Yale University received a $147,486 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded July 1, 2025, with a completion date of June 30, 2028. This research grant funds investigation into the role of glycosylated RNAs (glycoRNAs)—RNA molecules post-transcriptionally modified with sialylated-N glycans—in acute myeloid leukemia (AML). The project delivers scientific research outputs across three primary aims:...
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- Federal Grant Award Summary Yale University received a $610,637 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded April 1, 2026, with completion targeted for March 31, 2031. The grant funds bioengineering research to develop an optimized drug delivery platform utilizing bioadhesive and non-adhesive biodegradable nanoparticles for locoregional treatment of advanced melanoma. The research will engineer nanoparticles with selective...
- Federal Grant Award Summary Yale University received a $167,771 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion targeted for July 31, 2027. The award supports research to elucidate the mechanisms of a novel human-specific immune checkpoint interaction between SIGLEC-7 and VSIG4 proteins. The research will utilize a humanized mouse platform (MISTRG6-A2) to develop in vivo models that investigate how...
- Cooperative Agreement Award Summary Yale University received a $251,360 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate multiplexed quantitative immunofluorescence (MQIF) assays for improved patient stratification in cancer immunotherapy and PARP inhibitor treatments. The award, effective September 1, 2025, through August 31, 2027, addresses the unmet clinical need for predictive biomarkers...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput technological tools for tracking the fate of prematurely terminated transcripts in cancer cells. The project, which extends through February 28, 2029, focuses on advancing understanding of alternative polyadenylation (APA) events—RNA processing mechanisms that drive oncogenesis independent of DNA...